Boston Scientific, Inc. BSX recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of ...

MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ ...

Boston Scientific Corporation (NYSE:BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields ...

Boston Scientific just became the second company to cross the FDA finish line in the pulsed field ablation (PFA) market. The company's Farapulse PFA system, which was first-to-market in Europe, is one ...

GREENVILLE, N.C. (WITN) - An Eastern Carolina hospital recently performed its first procedure with a new and innovative device that treats an irregular heartbeat. In September, ECU Health Cardiology ...

Editor's note: This is the first of a two-part series on the Boston Scientific Investor Day presentation. This first part focuses on the company's Farapulse pulsed field ablation system. Part two will ...

Boston Scientific has received US Food and Drug Administration (FDA) approval for the Farapulse Pulsed Field Ablation (PFA) system for the isolation of pulmonary veins in the treatment of ...

KPJ Kluang Specialist Hospital (“KPJ Kluang”), part of KPJ Healthcare Berhad’s (“KPJ Healthcare” or the “Group”) network of hospitals, has successfully performed Southern Malaysia’s first FARAPULSE ...

PADUCAH, Ky. (KFVS) - Baptist Health Paducah is offering a new device to treat intermittent atrial fibrillation or an irregularly fast heart rate. According to a release from Baptist Health, Vedran ...

Consultant Cardiologist and Electrophysiologist at KPJ Kluang Specialist Hospital, Dr Ng Kim Fong (standing, second from left), Medical Director of KPJ Kluang Specialist Hospital, Dr Ong Shuh ...

Boston Scientific Corporation BSX released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields ...